Effects of new quinizarin derivatives on both HCV NS5B RNA polymerase and HIV-1 reverse transcriptase associated ribonuclease H activities

Journal of Chemotherapy

Volumn 23, Issue 5, 2011, Pages 273-276

  Tramontano, E ^a   Kharlamova, T ^a   Zinzula, L ^a   Esposito, F ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

HCV; HCV RNA dependent RNA polymerase (RDRP) NS5B; HIV 1; Quinizarin derivatives; Ribonuclease H (RNase H); RNA dependent DNA polymerase activity (RDDP)

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS C VIRUS RNA DEPENDENT RNA POLYMERASE NS5B; QUINIZARIN; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED RNA POLYMERASE INHIBITOR; RNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS RNA; 1,4-DIHYDROXYANTHRAQUINONE; ANTHRAQUINONE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DNA DIRECTED RNA POLYMERASE; INTERCALATING AGENT; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; RECOMBINANT PROTEIN; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; VIRUS PROTEIN;

ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA REPLICATION; DRUG SYNTHESIS; ENZYME ACTIVITY; IC 50; INTERCALATION COMPLEX; NONHUMAN; CELL LINE; CELL SURVIVAL; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; GENETICS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REPLICON; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANTHRAQUINONES; ANTI-HIV AGENTS; CELL LINE; CELL SURVIVAL; DNA-DIRECTED RNA POLYMERASES; DRUG DESIGN; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; INTERCALATING AGENTS; RECOMBINANT PROTEINS; REPLICON; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS; RNA REPLICASE; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84857721005     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2011.23.5.273     Document Type: Article

References (23)

1. Kim AY, Chung RT. Coinfection With HIV-1 and HCV -a one-two punch. Gastroenterology 2009; 137: 795-814.
2. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HiV Outpatient study investigators. Engl J Med 1998; 338(13): 853-860.
3. Murphy EL, Collier AC, Kalish LA, Assmann SF, Para MF, Flanigan TP et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. J Ann intern Med 2001; 135(1): 17-26.
4. Tsou LT, Deutschmann EG, Gullen EA, Telpoukhovskaia M, Cheng YC, Hamilton AD. Discovery of a synthetic dual inhibitor of HIV and HCV infection based on a tetrabutoxy-calix [4]arene scaffold. Bioorg Med Chem Lett 2010; 20 (7): 2137-2139.
5. Mehellou Y, De Clercq E. Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? J Med Chem 2010; 53: 521-538.
6. Tramontano E. The exploding field of the HCV polymerase non-nucleoside inhibitors: summary of a first generation compounds. Mini Rev Med Chem 2008; 8(12): 1298-1231.
7. Tramontano E, Di Santo R. HiV-1 RT-associated Rnase H function inhibitors: recent advances in drug development. Curr Med Chem 2010; 17: 2837-2853.
8. Priebe W. Anthracycline Antibiotics: new analogues, Method of Delivery, and Mechanisms of Action (ACs symposium) ed. Waldemar Priebe 1995.
9. Arcamone F M. From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie 1998; 80 (3): 201-206.
10. Smith A L, Nicolaou K C. The enedyne antibiotics. J Med Chem 1996; 39(11): 2103-2117.
11. Faulds D, Balfour J A, Chrisp P, Langtry HD. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991; 41(3): 400-449.
12. De Riccardis FD, Izzo I, Di Filippo M, Sodano G, D'Acquisto F, Carnuccio R. synthesis and cytotoxic activity of steroid-anthraquinone hybrids. Tetrahedron 1997; 53 (31): 10871-10882.
13. Sokolyuk NT, Romanov VV, Pisulina LP. Naphthacenequinones: synthesis and properties. Russian Chem Rev. 1993; 62 (11): 1005-1024.
14. Lowen JW. Anthracycline and anthracenedione based anticancer agents: current status and recent developments. Pharmacol Ther 1993; 60 (2): 185-214.
15. Kharlamova T, Esposito F, Zinzula L, Floris G, Cheng YC, Deutschmann EG, et al. Inhibition of HiV-1 Ribonuclease H activity by a novel frangula-emodine derivative, 7-brom-6-phenacyl-1,8-dihydroxy-3-methylanthraquinone. Med Chem 2009; 5(5): 398-410.
16. Esposito F, Kharlamova T, Distinto S, Zinzula L, Cheng Y-L, Deutschmann EG, et al. Alizarine derivatives as new dual inhibitors of the HiV-1 reverse transcriptase (RT)-associated DnA polymerase and Ribonuclease H (Rnase H) activities effective also on the Rnase H activity of nonnucleoside resistant RTs. FEBs J. 2011, doi: 10.1111/j.1742-4658.2011.08057.x.
17. Tramontano E, Cheng YC. Hiv-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: Bi-RG-587. Biochem Pharmacol 1992;43(6): 1371-1376.
18. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HiV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiv Res 2005; 65(2): 117-124.
19. Starnes MC, Cheng YC. Human immunodeficiency virus reverse transcriptase- associated Rnase H activity. J Biol Chem 1989; 264(12): 7073-7077.
20. Benzaria S, Bardiot D, Bouisset T, Counor C, Rabeson C, Pierra C, et al. 2'-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RnA virus replication. Antivir Chem Chemother 2007; 18(4): 225-242.
21. Koyama M, Takahashi K, Chou TC, Darzynkiewicz Z, Kapuscinski J, Kelly TR et al. intercalating agents with covalent bond forming capability. A novel type of potential anticancer agents. 2. Derivatives of chrysophanol and emodin. J Med Chem 1989; 32(7): 1594-1599.
22. Koyama J, Inoue M, Morita I, Kobayashi N, Osakai T, Nishino H. et al. Correlation between reduction potentials and inhibitory effects on Epstein- Barr virus activation by emodin erivatives. Cancer Lett 2006; 241(2): 263-267.
23. Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudinesusceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990; 34(3): 436-441.